Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2021 Oct 29;10(1):1995166. doi: 10.1080/2162402X.2021.1995166

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2021 The Author(s). Published with license by Taylor & Francis Group, LLC.

This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial License (http://creativecommons.org/licenses/by-nc/4.0/), which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.

PMC Copyright notice

Figure 2. — Diagnostic and prognostic value of CD9-CD63 signal detected by SiMoa in patients with DLBCL. (a) The CD9-CD63 signal in DLBCL and healthy subjects measured by SiMoa. (b) ROC analysis to evaluate the diagnostic power to differentiate DLBCL cases (n = 164) from the healthy controls (n = 25) with CD9-CD63 assay. (c-f) The association of CD9-CD63 signal with molecular subtype, the number of extranodal sites, tumor mass and CR status after treatment. (g, h) The progression-free survival (PFS) and overall survival (OS) in the high and low CD9-CD63 signal group. (i) CD19 and CD20 expression on the plasma EVs detected by western blots. (j-k) CD19 and CD20 expression on the plasma EVs observed by flow cytometry